Literature DB >> 27406584

Utility of MRI versus tumor markers for post-treatment surveillance of marker-positive CNS germ cell tumors.

Victoria Cheung1, Devorah Segal2, Sharon L Gardner3, David Zagzag4, Jeffrey H Wisoff5, Jeffrey C Allen6, Matthias A Karajannis7,8.   

Abstract

Patients with marker-positive central nervous system (CNS) germ cell tumors are typically monitored for tumor recurrence with both tumor markers (AFP and b-hCG) and MRI. We hypothesize that the recurrence of these tumors will always be accompanied by an elevation in tumor markers, and that surveillance MRI may not be necessary. We retrospectively identified 28 patients with CNS germ cell tumors treated at our institution that presented with an elevated serum or cerebrospinal fluid (CSF) tumor marker at the time of diagnosis. We then identified those who had a tumor recurrence after having been in remission and whether each recurrence was detected via MRI changes, elevated tumor markers, or both. Four patients suffered a tumor recurrence. Only one patient had simultaneously elevated tumor markers and MRI evidence of recurrence. Two patients had evidence of recurrence on MRI without corresponding elevations in serum or CSF tumor markers. One patient had abnormal tumor markers with no evidence of recurrence on MRI until 6 months later. We conclude that in patients with marker-positive CNS germ cell tumors who achieve complete remission, continued surveillance imaging in addition to measurement of tumor markers is indicated to detect recurrences.

Entities:  

Keywords:  CNS tumors; Germ cell tumors; Surveillance MRI; Tumor markers

Mesh:

Substances:

Year:  2016        PMID: 27406584     DOI: 10.1007/s11060-016-2207-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  6 in total

1.  Multimodality therapy for CNS mixed malignant germ cell tumors (MMGCT): results of a phase II multi-institutional study.

Authors:  Patricia L Robertson; Regina Jakacki; Juliette Hukin; Joao Siffert; Jeffrey C Allen
Journal:  J Neurooncol       Date:  2014-04-04       Impact factor: 4.130

2.  Pattern of relapse after first line treatment of advanced stage germ-cell tumors.

Authors:  A Fléchon; S Culine; C Théodore; J-P Droz
Journal:  Eur Urol       Date:  2005-07-18       Impact factor: 20.096

3.  Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumor.

Authors:  Karin Oechsle; Anja Lorch; Friedemann Honecker; Christian Kollmannsberger; Jörg T Hartmann; Ina Boehlke; Jörg Beyer; Carsten Bokemeyer
Journal:  Oncology       Date:  2010-03-06       Impact factor: 2.935

4.  Marker (+) CNS germ cell tumors in remission: are surveillance MRI scans necessary?

Authors:  Sybila Martinez; Yasmin Khakoo; Stephen Gilheeney; Kim Kramer; Suzanne Wolden; Mark Souweidane; Ira J Dunkel
Journal:  Pediatr Blood Cancer       Date:  2013-12-03       Impact factor: 3.167

5.  Epidemiological survey of central nervous system germ cell tumors in Canadian children.

Authors:  D Keene; D Johnston; D Strother; C Fryer; A S Carret; B Crooks; D Eisenstat; A Moghrabi; B Wilson; J Brossard; C Mpofu; I Odame; S Zelcer; M Silva; Y Samson; J Hand; E Bouffet
Journal:  J Neurooncol       Date:  2006-11-22       Impact factor: 4.506

6.  A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.

Authors:  Nathan J Robison; Federico Campigotto; Susan N Chi; Peter E Manley; Christopher D Turner; Mary Ann Zimmerman; Christine A Chordas; Annette M Werger; Jeffrey C Allen; Stewart Goldman; Joshua B Rubin; Michael S Isakoff; Wilbur J Pan; Ziad A Khatib; Melanie A Comito; Anne E Bendel; Jay B Pietrantonio; Laura Kondrat; Shannon M Hubbs; Donna S Neuberg; Mark W Kieran
Journal:  Pediatr Blood Cancer       Date:  2013-10-04       Impact factor: 3.167

  6 in total
  3 in total

1.  The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors.

Authors:  Hideo Nakamura; Hirokazu Takami; Takaaki Yanagisawa; Toshihiro Kumabe; Takamitsu Fujimaki; Yoshiki Arakawa; Katsuyuki Karasawa; Keita Terashima; Hideaki Yokoo; Kohei Fukuoka; Yukihiko Sonoda; Kaori Sakurada; Yohei Mineharu; Toshinori Soejima; Motoaki Fujii; Naoki Shinojima; Junichi Hara; Kai Yamasaki; Junya Fujimura; Fumiyuki Yamasaki; Mayu Takahashi; Tomonari Suzuki; Iori Sato; Ryo Nishikawa; Kazuhiko Sugiyama
Journal:  Neuro Oncol       Date:  2022-04-01       Impact factor: 13.029

2.  Roles of Tumor Markers in Central Nervous System Germ Cell Tumors Revisited with Histopathology-Proven Cases in a Large International Cohort.

Authors:  Hirokazu Takami; Christopher S Graffeo; Avital Perry; Caterina Giannini; Yoichi Nakazato; Nobuhito Saito; Masao Matsutani; Ryo Nishikawa; Koichi Ichimura; David J Daniels
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639

3.  Simultaneous intracranial and testicular germ cell tumors: illustrative case.

Authors:  Lei Han; Jie Lu; Luxiong Fang; Songtao Qi; Ye Song
Journal:  J Neurosurg Case Lessons       Date:  2021-01-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.